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Staphylococcus aureus (S.aureus) is a successful opportunistic human pathogen, causing 
superficial infections such as skin and soft tissue infections as well as invasive fatal ones 
including endocarditis, pneumonia and septicemia with high mortality. It represents one of the 
growing public health concerns worldwide since the rapid spreading of multi-antibiotic 
resistant S.aureus strains has increased the failure of therapeutics, urgently calling for 
pathogenesis research and development of effective treatment strategies.  
 
30% of the population carries S.aureus on the skin and mucous membranes where the pH is 
usually mild acidic (average 4 to 6). Managing survival under this environment is a critical 
step for S.aureus successful colonization, dissemination and infection. The cell wall, a multi-
layered protective structure, plays a crucial role in maintaining S.aureus viability under hostile 
surroundings. Lipoteichoic acids (LTA) are one type of the main components of the S.aureus 
cell wall, composed of repeating glycerol phosphate units and a glycolipid anchor called 
diglucosyl-diacylglycerol (Glc2-DAG) that fixes LTA polymers on the outer leaflet of the 
plasma membrane. Glc2-DAG is synthesized in the cytoplasm and transferred across the 
plasma membrane by the integral membrane protein LtaA (lipoteichoic acid protein A). The 
deletion of LtaA in S.aureus led to the alteration of the LTA anchor from Glc2-DAG to 
diacylglycerol (DAG) and attenuated virulence during animal infection.  
 
LtaA belongs to transporters that mediate glycolipid translocation. This category is closely 
involved in the cell wall biosynthesis by transferring multiple precursors or molecules to 
satisfy the proper assembly of the cell wall. Bacteria harbor diverse glycolipid transporters, 
most of which are not well understood. LtaA was predicted to belong to the major facilitator 
superfamily (MFS), a large family of membrane proteins that are ubiquitously distributed in 
all kingdoms of life, transferring a broad range of substrates from sugars, peptides to ions and 
lipids across membranes. Research on MFS transporters involved in glycolipids transport is 
scarce, hindering the understanding of their flipping mechanisms.  
 
In this study, we determined the structure of LtaA by X-ray crystallography at a resolution of 
3.3 Å. LtaA presents the canonical MFS fold with 12 transmembrane helices (TMs) arranged 
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in two pseudo-symmetric sub-domains, N-domain (TM1-6) and C-domain (TM7-12). A 
striking feature is the presence of a large amphiphilic central cavity which we hypothesized to 
accommodate the amphiphilic substrate Glc2-DAG. By analyzing LtaA crystal structure, along 
with site-direct mutagenesis and transport assays in vitro, we demonstrated that the di-glucosyl 
moiety of Glc2-DAG is recognized by multiple conserved hydrophilic residues located in the 
N-terminal domain and loaded to the central cavity. We also proposed a proton-coupling 
mechanism where E32 undergoes protonation/deprotonation, and this extra driving force 
allows Glc2-DAG to be translocated at a higher rate. By investigating LtaA function in 
S.aureus, we revealed that the proton-coupling mechanism allows LtaA to act as an 
environmental pH sensor and contribute to the survival of S.aureus under an acidic 
environment. Our results provided insights into the molecular basis of Glc2-DAG flipping and 
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1   Introduction 
1.1 Staphylococcus aureus  
 
Staphylococcus aureus (S.aureus) is a Gram-positive bacterium of Firmicutes phylum with a 
size between 0.5–1.5 µm in diameter, which forms irregular grape-like clusters1 (Fig. 1.1). It 
serves as a successful opportunistic human pathogen since the first description of the 
staphylococcal disease in 18802,3. As a commensal bacterium, it is carried by more than 30% 
of the population, and around 10%-20% is the persistent colonization4,5. Sites can be colonized 
by S.aureus including anterior nares, axilla, pharynx, gastrointestinal tract, vagina and 
perineum4. Colonized people with S.aureus are at a higher risk to get infected6. As a versatile 
pathogen, it invades breaches on skin or mucus membranes, causing various skin and soft 
tissue infections. S.aureus can further spread to distant organs, leading to life-threatening 
diseases including infective endocarditis, pleuropulmonary and septicemia7. S.aureus is highly 
contagious and can be transmitted to a new host through everything that can contact the skin 
or mucus membranes, such as clothes, smartphones or medical devices8. Notably, the 
transmission through various medical materials facilitates S.aureus infection as one of the 
leading causes of healthcare facility acquired infections including prosthetics, catheters and 
other implant devices related infections9. Invasive diseases caused by S.aureus are often 
associated with a big burden of morbidity and mortality (nearly 20% mortality), making 
treatments against this bacterium an unmet medical need for more than 100 years5,10. The 
occurrence and the quick spread of multiple drug resistance strains, such as methicillin-
resistant S. aureus (MRSA) against β-lactams and vancomycin-resistant S. aureus (VRSA) 
resistant to the so-called last line medicine vancomycin11,12, increase thereby the failure of 
therapeutics and health burden caused by S.aureus infection. In 2018, the percentage of MRAS 
isolates ranged from 5% to 43% in middle and south Europe13. It has been estimated that 
MRSA causes over 150,000 cases and an extra EUR 380 million costs of treatments annually 
in Europe14,15. Thus, S.aureus has been identified as one of ESKAPE pathogens (Enterococcus 
faecium, S. aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa, and Enterobacter species) that are the most common causes of life-threatening 
infections, requiring intensive research and development of therapies with high priority16.  
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Fig. 1.1  Observation of S. aureus by Scanning Electron Microscopy. The scale bar indicates 6 μm.  
Adapted from17 
 
1.2 Cell wall of S.aureus 
 
To sustain its colonization, dissemination and infection of human hosts, S.aureus has to survive 
under various hostile environments. The nature reservoirs include the skin where it is dry, 
mildly acidic (average pH is between 4 to 6) and with a high concentration of salt, moisty and 
mildly acidic mucosal membranes and host macrophages where the environment is also 
acidic1,5. Besides these harsh physical conditions, S.aureus will also encounter anti-bacterial 
substances on skin and mucosal membranes as well as phagosomes and lysosomes in 
macrophages, which are all harmful to S.aureus5. The S.aureus cell wall is a multi-layered 
protective structure (typically 30-80 nm) that maintains the cell integrity, helps in 
pathogenicity and protects it from toxins, host defenses and antibiotics18,19. Thus, it serves as 
the first line of bacterial defense as it interacts directly with various environments and provides 
S.aureus high adaptability towards harmful surroundings1. Like the other Gram-positive 
bacteria, S.aureus presents a cell wall composed of thick peptidoglycan (PG) multilayer and 
long polymers called teichoic acids19–21 (Fig. 1.2). PG consists of disaccharides cross-linked 
by peptide side chains, accounting for around 50% weight of the cell wall1,5. Teichoic acids 
are long polymers containing repetitive polyol phosphate subunits. The cell wall also harbors 
many surface proteins that process diverse functions, such as substance exchange, host 
interaction (adhesion, invasion, conjugation and immune evasion) and environment stimulus 
sensing5,16.   
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Fig. 1.2  The cell wall of S.aureus. A: Observation of the cell wall by Transmission Electron  
Microscopy. Adapted from17. B: Scheme of the cell wall with teichoic acids highlighted. Adapted 
from2 
 
Due to the fundamental role of the cell wall in bacteria, it has been treated as a hotspot for 
antibiotics development. Many star antibiotics used in clinical target the cell wall biosynthesis 
pathway, especially the PG assembly pathway that is highly conserved in a broad spectrum of 
bacteria22. β-lactams are the most clinically used antibiotics containing thousands of 
derivatives (such as penicillin V, ampicillin, methicillin, oxacillin) since Alexander Fleming 
discovered that benzylpenicillin could kill staphylococci effectively in 1920s23,24. β-lactams 
bind to penicillin-binding proteins (PBPs) involved in the cross-linking step of PG synthesis, 
interfering with the cell wall assembly and resulting in cell rupture23. Another type is 
glycopeptides/glycolipopeptides (such as vancomycin, teicoplanin), also disrupting the cross-
linking step of PG by binding to the natural substrate of PBPs, the D-alanyl-D-alanine moiety25.  
 
However, resistance to one or several antibiotics occurred quickly and spread worldwide26. 
S.aureus first developed the penicillin resistance by obtaining penicillinase that can hydrolyze 
the effective module of penicillin, the β-lactam ring27. To date, resistance to many β-lactams 
is also related to the updated β-lactamase of S.aureus23. Penicillin resistance led to the 
development of new penicillin derivatives that are insensitive to penicillinase, such as 
methicillin and oxacillin. However, the widespread use of penicillin derivatives led to the 
appearance of methicillin-resistant strains, by acquiring the major resistant-related gene mecA 
encoding a protein PBP2a or mecC encoding PBP2aLGA that display low binding affinity to the 
whole β-lactams27,28. Subsequently, vancomycin was applied to treat invasive MRSA 
infections in 1980s29. Vancomycin resistance in S.aureus was also observed afterward with an 
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enhanced minimum inhibitory concentration (MIC) from ≤2 μg/ml to＞16 μg/ml30. It’s 
believed that the occurrence of VRSA is a result of acquiring multiple resistant-related genes 
that have not been fully characterized so far31. One of the major contributors to vancomycin 
resistance is the van cluster involved in the synthesis of D-alanyl-D-lactate or D-alanyl-D-
serine which are the substitutions of D-alanyl-D-alanine and display low affinity to 
vancomycin30. Although the occurrence of VRSA is not as much as MRSA, VRSA poses a 
potential health threat, which exhorts a more detailed understanding of S.aureus cell wall 
biosynthesis and the identification of new targets for next-generation antibiotics development.  
   
1.3 Lipoteichoic acids 
 
Teichoic acids are crucial cell wall components identified by Baddiley and coworkers in 
195832, who named them in reference to teīkhos which means “fortification wall” in Greek, 
highlighting their importance in cell protection33. Teichoic acids are roughly classified into 
two types: wall teichoic acids (WTA), which are bound to the peptidoglycan, and lipoteichoic 
acids (LTA), which are anchored to the cell membrane2.  
 
LTA molecules are composed of polymerized polyol phosphate units through phosphodiester 
bonds and a glycolipid anchor, being retained in all Gram-positive bacteria except some 
Micrococcus strains34,35. According to the difference in the chemical structure, there are five 
types of LTA identified36(Fig. 1.3). S.aureus contains the simplest and the best-characterized 
type I LTA33 composed of 1,3-linked glycerol phosphate repeating units (average 25 units37) 
which are tethered to the membrane by a glycolipid linker diglucosyl-diacylglycerol (β-
glycosyl(1–6)-β-glucosyl(1–3)-diacylglycerol, Glc2-DAG) inserted in the extracellular side of 
cell membrane38 (Fig. 1.4). The terminal phosphate of polymerized units is linked to the 
hydroxyl group at the C6 position of the glucosyl moiety of Glc2-DAG
38. Hydroxyl groups at 
the C2 position of glycerol phosphate moieties are commonly decorated with D-alanyl or 
glycosyl groups39. LTA molecules are relatively abundant in the plasma membrane of S.aureus, 
accounting for every ninth lipid on the outer leaflet of the plasma membrane34. 
 




Fig. 1.3  Representative cartoon of type I-V LTA. Gro, glycerol; Glc, glucose; A, D-alanine; P: 
phosphate; Gal, galactose; GlcNAc, N-acetylglucosamine; C, choline; AAT-Gal, 2-acetamido-4-amino-






Fig. 1.4  Formula of a lipoteichoic acid molecule of S.aureus. R2: 60%-70% D-alanine, 15%: N-
acetylglucosamine, 15% H. Percentages indicate the proportion of the substation in lipoteichoic acids. 
Adapted from 41.  
 
The glycolipid anchor Glc2-DAG is also abundant, counting 7% of the plasma membrane
42. 
The lipid tail lengths vary between 14 carbons to 21 carbons, among which the richest is 
C15:0/C17:042 (Fig. 1.5). To sustain proper LTA polymer assembly in the extracellular side, 
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the anchor must be transferred to the outer leaflet of the cell membrane, which makes it a 
crucial step by determining the available anchor level for proper LTA assembly. 
 
 
Fig. 1.5  Scheme of diglucosyl-diacylglycerol (Glc2-DAG). R indicates the lipid tail, varying from 14-
21 carbons.    
 
1.3.1 Biosynthesis pathway of LTA  
 
Key enzymes involved in S.aureus LTA biosynthesis have been identified (Fig. 1.6). The 
biosynthesis of LTA in S.aureus begins from the assembly of the glycolipid anchor Glc2-DAG 
in the cytoplasm. Glucose-6-phosphate is converted into glucose-1-phosphate by an enzyme 
called PgcA43. Another enzyme GtaB catalyzes glucose-1-phosphate to its nucleotide-
activated form, the uridine diphosphate glucose (UDP-Glc)43. The glycosyltransferase Ypfp 
adds two UDP-Glc units processively to DAG to form Glc2-DAG
44,45. Glc2-DAG is then 
transferred across the cytoplasm membrane as the anchor of glycerol phosphate 
polymerization that happens on the extracellular side of the membrane44,46. This translocation 
step is facilitated by the putative membrane translocase LtaA44. LtaS then builds the polymer 
by iteratively adding the glycerol phosphate units originated from phosphatidylglycerol to the 
anchor Glc2-DAG
47. This step releases DAG molecules which are then converted to 
phosphatidic acid by DgkB as the precursor for the biosynthesis of new phosphatidylglycerol 
molecules48. The C2 hydroxyl position of glycerol groups of LTA can be decorated with D-
alanine moieties (around 60%-70% depending on the strains39) by four concerted Dlt proteins, 
DltABCD20,49 or glycosyl groups (around 15%43) by CsbB, GtcA and YfhO39. LTA molecules 
display a zwitterionic property because of negatively charged phosphate moieties and free 
amino groups of incorporated alanine moieties20,50.  
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Fig. 1.6  The biosynthesis pathway of the LTA in S.aureus. Glc, glucose; UDP-Glc, uridine 
diphosphate glucose; GroP, glycerol phosphate; DAG, diacylglycerol; Glc2-DAG, diglucosyl-
diacylglycerol. Adapted from2,51. 
 
1.3.2 Functions of LTA 
 
As a constituently expressed cell wall component, LTA participates in maintaining cell wall 
mechanic rigidity and contributes to the osmotic protection of the cell. The LTA knockout 
strain (ltaS deletion) could only survive under experimental high osmotic conditions (such as 
the supplement of either 7.5% NaCl or 40% sucrose in the culture medium) or lower 
temperature (from 37 ℃ to 30 ℃), but with morphological defects52,53. Faster lysis under 
Triton X-100 solution was observed in the ypfP inactive strain45. It has been suggested that 
LTA contributed to the osmotic protection by influencing the PG layer assembly54. A decreased 
cross-linking level of the PG layer was observed in LTA depletion strain54. Spontaneous 
mutations that increased the cross-linking level of PG, such as mutations on gdpP which 
regulates the cross-linking level of PG through controlling the intracellular di-adenosine 
monophosphate (c-di-AMP) level53 or on sgtB, a PG glycosyltransferase which directly 
participates in PG assembly54, were proposed to allow the cell survival without LTA molecules.   
 
LTA also contributes to cell division since it is deeply involved in maintaining cell wall 
structure. Defects in cell division, such as aberrant size, aberrant shape and aberrant 
positioning of division septa, were observed in ltaS, ypfP or ltaA deletion S.arueus 
strains47,52,55. These defects were attributed to the absence of LTA, which disrupts the 
interaction between LTA and the cell elongation and division machinery. Specifically, it was 
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reported that the interaction between LTA and the following proteins is disrupted, FtsZ, which 
allows the initiation of cell division by forming the Z-ring structure at the division site56–58, 
ClpX, which was proposed to be a modulator of FtsZ59 and autolysins which enable the 
separation of daughter cells60,61. Thus, LTA help in the localization of division machinery58 
and the regulation of the autolytic activity47,61. Because the autolysin activity was reported to 
relate to Mg2+ concentration62, the regulation of autolytic activity was credited to the control 
of Mg2+ concentration through the D-alanylation level of LTA molecules61,63,64. Furthermore, 
participating in Mg2+ regulation renders LTA a pivotal contributor to extracellular ion 
homeostasis63.   
 
As a crucial part of the cell wall, the front line to interact with hosts, LTA molecules interact 
with many host receptors involved in inflammatory response, colonization and infection 
process. Hosts recognize pathogens and induce innate immune response via highly-conserved 
pattern recognition receptors (PRRs) including Toll-like receptors and C-type lectin 
receptors65,66. Toll-like receptors recognize many pathogen-associated substances and initiate 
proinflammatory responses to eliminate pathogens, but there is a risk for them to induce sepsis 
with the same mechanism67. LTA was proposed to interact with Toll-like receptors 2 (TLR2) 
expressed on epithelial as well as endothelial cells and D-alanine moieties of it play a key role 
in inducing immune response68–70. L-ficolin, a C-type lectin receptor, was documented to bind 
LTA, activating the complement pathway and pathogen opsonization71. LTA has also been 
documented to interact with many receptors of macrophages and monocytes, including type I 
macrophage scavenger receptor localized at the surface of macrophages as a part of the innate 
pathogen recognition system72 and CD36 helping with the TRL2-related inflammatory 
signaling69,73. LTA was proposed to participate in the formation of biofilm74,75,which facilitates 
the colonization of S.aureus and helps it in the resistance to harmful environments76–78.  
   
Of note, LTA molecules promote the resistance to anti-bacterial substances such as cationic 
antimicrobial peptides (CAMPs) and cationic antibiotics by their D-alanine decoration which 
enhances the positive charge and repels CAMPs and cationic antibiotics64,79–82. LTA was also 
demonstrated to participate in developing the resistance to daptomycin that belongs to the 
lipopeptide antibiotics applied as the last resort for MRSA infections83,84.  
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1.3.3 LTA serve as a target to develop anti-S.aureus infection therapeutics  
 
LTA molecules act as crucial cell wall components and display versatile roles in S.aureus 
pathogenesis, which make it a potential target for the development of novel anti-S.aureus 
strategies. Research on LTA-targeted treatments including developing antibiotics, conjugated 
antibodies and vaccines has been carried out in different labs. A small inhibitor targeting LtaS 
was developed named compound 177185. Nevertheless, compound 1771 contains an ester 
moiety which might be hydrolyzed by esterase in the blood86. HSGN‐189 was proposed to 
inhibit LTA biosynthesis, displaying a high MRSA killing ability (MIC= 0.25 mg/mL)86. 
Pagibaximab, a human chimeric monoclonal antibody against LTA, displayed an impressive 
staphylococcal killing effect, but it failed in Phase II because no significant protective effect 
against staphylococcal sepsis was observed in very low birth weight neonates trial87. Several 
molecules that mimic LTA structure or the epitope of LTA, such as synthetic ploy-
glycerolphosphate polymers88, a short peptide (12 amino acids)89 or even LTA from other 
species90 have been proposed to induce protective effects and ameliorate S.aureus infection in 
animal models. However, the LTA-targeted clinical usage remains largely vacant, partly owing 
to the fact that the molecular basis of its biosynthesis, functions and interactions with hosts are 
not well known. Notably, the 3D structures of many crucial proteins involved in LTA 
biosynthesis remain to be characterized, such as YpfP, LtaA and full-length LtaS (extracellular 
domain has been solved46). Solving the structure of these proteins will pave the way to the 
understanding of LTA biosynthesis and the application of LTA-derivative therapeutics.   
1.4 Putative Glc2-DAG translocase LtaA    
 
LtaA is the putative candidate that facilitates the translocation of Glc2-DAG across the plasma 
membrane, identified by Angelika Gründling and Olaf Schneewind in 200644. Gene MU50 
(locus tag SAV1016, Uniport ID: Q99V76) was denoted to ltaA, whose predicted start overlaps 
to the end of the ypfP coding sequence, and it could be found in all close-related species of 
S.aureus (such as Staphylococcus epidermidis, Staphylococcus haemolyticus and 
Staphylococcus saprophyticus)44. As the translocase of the anchor of LTA, LtaA plays an 
essential role in proper LTA assembly. The knockout of ltaA gene in S.aureus abolished the 
flip of Glc2-DAG and led to the assembly of LTA on DAG
44. The change of the anchor 
influenced the distribution of LTA because more LTA molecules were released to the 
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supernatant44. This change also led to the reduction of virulence during animal infection44. 
More recently, LtaA has been proposed to involve in developing daptomycin resistance which 
is influenced by the Glc2-DAG level of LTA
83. More questions in-depth, such as how does 
LtaA conduct the Glc2-DAG translocation, how does the anchor flipping coordinate to the LTA 
biosynthesis and what is the regulatory mechanism remain unknown. Solving the structure of 
LtaA will facilitate tackling these questions and promoting the application of LtaA-targeted 
anti-S.aureus therapeutics.   
 
1.5 Transport systems 
 
The cell membrane is mainly composed of a phospholipid bilayer, forming a two-dimensional 
semipermeable barrier. It defines the boundary of the organism and its environment, regulating 
many exchanges of essential substances with the environment91. Except for a few small 
molecules that can diffuse freely across the lipid bilayer, and some bulky substances (such as 
pathogens and dead cells) can be exchanged by the endocytosis and exocytosis process, the 
transmembrane transport of most solutes is mediated by transport protein systems92. Transport 
proteins allow the uptake of nutrients and ions, excretion the deleterious and communication 
between the cell and the environment, serving the cell in many aspects, including cell growth 
and cell division, metabolism and signal transduction92.  
 
Two major types of transport proteins are channels and transporters93 (Fig. 1.7). Channels can 
open the cytoplasmic side and the extracellular side simultaneously, while transporters can 
only open one side at the same time93. Open both sides when activated only allows channels 
to transfer the substrates downhill their electrochemical gradients. Thus, translocation against 
the substrate electrochemical gradient relies on the transporters.  
 
 
Fig. 1.7  Scheme of channels and transporters. Adapted from94  
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According to the transport mode and energy coupling, transporters are mainly divided into 
three groups: facilitators, primary active transporters and secondary active transporters93. 
Facilitators, also known as uniporters, belong to passive transporters. Energetically similar to 
channels, they transport targets only downhill the electrochemical gradient. Primary active 
transporters are driven by the energy from photons or chemical reactions such as the adenosine 
triphosphate (ATP) hydrolysis95. Primary active transporters contribute to generating an 
electrochemical potential across membranes by transporting charged molecules96. This 
electrochemical potential can act as the energy source of secondary active transporters to 
mediate the transport of substances across the membrane97. According to the relative 
movement direction, secondary active transporters are divided into symporters and antiporters. 
Symporters transfer the substrate and the driving solute in the same direction while antiporters 
transfer the two in a different direction98 (Fig. 1. 8). Further classification of transporters is 
determined by their structure fold, function, mechanism and substrate93. 
 
 
Fig. 1.8  Scheme of uniporters, symporters and antiporters. Adapted from98 
 
1.6 Glycolipid transporters 
 
Lipids and their conjugates are indispensable for living organisms, forming the cell 
membranes, serving as the energy storage source and participating in various signal 
transduction and metabolism99. Among all lipid conjugates, glycolipid, a ubiquitous and 
important component of the cell envelop of bacteria, has critical functions in maintaining cell 
integrity and contributing to the invasion and immune evasion from hosts100. They are 
generally synthesized from nucleotide-activated sugar precursors and lipid acceptors, followed 
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by the export process by specific transporters to participate in the building of PG, TA, capsular 
polysaccharide (CPS), lipopolysaccharide (LPS), etc.100 The flip-flop of glycolipids with large 
and polar head groups is energetic unfavorable and serves as the rate-limiting step for 
transport101. To support the physiological requirement, it’s well accepted that the 
transmembrane transport of glycolipids is mediated by transporters101. A common type of 
glycolipid transporters is ATP-binding cassette (ABC) transporters. ABC transporters are 
primary active transporters with a broad range of substances, from small ions to large 
macromolecule102. Four structures of ABC transporters that mediate glycolipids transport have 
been solved so far including MsbA responsible for the lipid A translocation for LPS 
synthesis103, PglK that transports the lipids-linked glycan donor for protein N-glycosylation104, 
Wzm–Wzt that mediates the transport of the O-antigen for LPS bsynthesis105,106 and TarGH 
involved in WTA biosynthesis107. Both MsbA and PglK are type I ABC exporters consisting 
of two transmembrane domains (TMDs) forming the transport cavity and two cytoplasmic 
nucleotide-binding domains (NBDs) that perform ATP hydrolysis to energize the transport 
activity100,103,104 (Figure 1.9). In addition, PglK displays two unique short α-helices at the 
periplasmatic side running parallel to the membrane and might contribute to the interaction 
with its substrate104. Although they display similar structural distributions, two distinct 
transport mechanisms have been demonstrated. MsbA was proposed to take an “alternating 
access” mechanism where the substrate fully enters the binding pocket, and this is called a 
“trap and flip” model108,109 (Fig. 1.10 A). In contrast, an outward-only mechanism was 
proposed to PglK104 (Fig. 1.10 B). Outward-facing PglK recognizes the undecaprenyl moiety 
of undecaprenyl pyrophosphate (Und-PP) lipid carriers, whereas the hydrophilic headgroup is 
transported to the outward-open cavity104. Then ATP hydrolysis drives NBDs apart and TMDs 
together, squeezing the headgroup out of the binding pocket104. Wzm-Wzt presents a type II 
exporter fold, with channel-forming TMDs in an open conformation and closed nucleotide-
free NBDs106(Figure 1.9). Wzm-Wzt was assumed to recognize the pyrophosphate group of 
Und-PP together with the first sugar through the interface of NBD and its corresponding 
carbohydrate-binding domain (CBD)105,106, followed by the headgroup insertion and its 
spontaneously re-orientation to the periplasmic side, while the lipid tails probably remain in 
the membrane106 (Fig. 1.10 C). The translocation was possibly facilitated by multiple rounds 
of ATP binding and hydrolysis106. TarGH also displays a type II exporter fold similar to that 
of Wzm-Wzt107 (Figure 1.9). But TarGH was implicated to first interact with the 
pyrophosphate group of Und-PP only107. The flipping mechanism for TarGH is similar to that 
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of Wzm–Wzt107.  
 
Another type of glycolipid transporters is from the polysaccharide transport (PST) family, the 
multidrug/oligosaccharidyl-lipid/polysaccharide (MOP) superfamily of secondary 
transporters, such as Wzx for the O-antigen flipping110. However, no structure is available in 
this category. But the structure of MurJ from a close-related family to the PST family has been 
solved, providing some hints for glycolipid translocation by secondary transporters. MurJ is a 
lipid II (Und-PP-MurNAc-pentapeptide-GlcNAc) flippase involved in PG synthesis111. It 
contains 14 TMs divided into two lobes, TM1-6 and TM 7-14 respectively (Fig. 1.11). A Na+ 
interaction site and membrane potential were demonstrated to be essential for MurJ’s 




Fig. 1.9  Representative structures of ABC transporters. From the left to the right: MsbA with ADP-
vanadate (PDB: 5TTP); Outward-facing PglK with ATPgammaS bound (PDB: 6HRC); Wzt-Wzm 
(PDB: 6OIH) and TarGH in inward-facing conformation (PDB: 6JBH). Transporters are colored in 
rainbow.    
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Fig. 1.10  Schematic illustration of translocation mechanisms of ABC flippases. A. Classical 
“alternating access” mechanism of MsbA. B. Outward-only mechanism of PglK. C. The flipping 
mechanism of Wzt-Wzm. The translocation of the polysaccharides might be facilitated by repeat cycles 




Fig. 1.11  Representative structure of MOP transporters. Inward-facing MurJ (PDB: 5T77) and lipid 
II. Transporters are colored in rainbow.    
 
LtaA was predicted to belong to the major facilitator superfamily (MFS) which displays 
distinct structural architecture from the PST transporters or ABC transporters44,115. The 
flipping mechanism was also expected to be different. The diversity of overall architectures 
and flipping mechanisms of glycolipid transporters indicates the complexity and significance 
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of glycolipid translocation in nature.   
 
Since the substrate recognition, binding and flipping mechanism of LtaA were expected to be 
more similar to MFS transporters than ABC transporters mediating glycolipid translocation, a 
brief introduction of MFS transporters regarding their overall structural fold, substrate binding 
and flipping mechanisms will be shown in the next section.  
 
1.7 Major facilitator superfamily 
 
1.7.1 General features of MFS transporters 
 
The major facilitator superfamily (MFS) of transporters (TCDB classification: #2.A.1, 
http://www.tcdb.org/) is the largest group of secondary transporters, which is ubiquitous in all 
kingdoms of life. It consists of more than 15,000 sequenced proteins, a number still growing 
rapidly thanks to genome sequencing116. In 1993, the bioinformatics researchers have already 
established the term of major facilitator superfamily that contained transporters mediating 
sugar (oligosaccharides) transfer, multidrug efflux, metabolites up-taken as well as organic 
and inorganic phosphate exchange117–119. Later, the major facilitator superfamily quickly 
expanded to 82 families. In addition to the substrates above, MFS transporters mediate the 
transport of amino acids and short peptides, organic and inorganic cations and anions, lipids, 
nucleobases and nucleotides119–121. Many MFS transporters are involved in diseases and are 
considered as important drug targets122. However, there is still a large amount of MFS 
transporters identified only by bioinformatic tools, and very little is known regarding their 
mechanism, such as the ones involved in glycolipid transport.  
 
Phylogeny and sequence analysis showed that MFS transporters generally consist of 400-600 
amino acids and share transmembrane topology similarities by dividing into 12 
transmembrane α helices, but the number of TMs can be extended to 14 or 24119,123,124. 12 TMs 
are connected by hydrophilic loops, and the N termini and C termini are located on the 
cytoplasmic side121,125. These 12 TMs are organized into two sub-domains, the N-domain 
(TM1-6) and the C-domain (TM7-12)125. Transporters from different families usually display 
low sequence similarity125. Although with low primary sequence similarity, three highly 
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conserved signature sequence motifs (Motif A-C) have been identified to be shared along MFS 
transporters126. The Motif-A (“G(X)3DRXGRR”) at the loop that joins TM2 to TM3 together 
with a motif-A-like sequence presented at the equivalent loop connecting TM8 and TM9 
serves as one of the most conserved regions of MFS symporters and antiporters127. Other 
conserved regions include Motif-B “R(X)2QG” in TM4 and Motif-C 
“G(X)8G(X)3GP(X)2GG” in TM5127–129. Not all three motifs are present in all MFS 
transporters. 
 
1.7.2 Structural characterizations of MFS transporters 
 
In 2003, the first structure of an MFS transporter, the lactose permease LacY from E.coli, was 
solved by X-ray crystallography, paving a way for understanding its transport mechanism as 
well as the general working mechanism of MFS transporters130. Later the same year, the 
structure of an sn-glycerol-3-phosphate/phosphate antiporter (GlpT) from E.coli was also 
elucidated131. Until now there are 27 unique MFS transporters known of 3D structure from six 
different families. Except for LacY, there are ten more involved in saccharides translocation, 
four of which are from bacteria and six are from eukaryotes, including E.coli fucose 
transporter FucP (with mutant N162A)132, melibiose/ Na+ symporter MelB from Salmonella 
typhimurium133, E.coli xylose/H+ symporter XylE134, Staphylococcus epidermidis glucose/H+ 
symporter GlcP135, human glucose transporter GLUT1136, human glucose transporter (with 
mutant N45T) GLUT3137, fructose transporter GLUT5 from Bos Taurus and Rattus 
norvegicus138, sugar transport 10 from Arabidopsis thaliana139 and a hexose transporter from 
Plasmodium falciparum140. Seven of them are short peptide transporters from bacteria: 
oligopeptide/H+ symporter PepTSo from Shewanella oneidensis
141, oligopeptide/H+ symporter 
PepTSt from Streptococcus thermophilus
142, a proton-dependent oligopeptide transporter from 
Geobacillus kaustophilus143, E.coli peptide transport YgbH144, Yersinia enterocolitica 
dipeptide transporter145, Xanthomonas campestris peptide transporter PepTXc
146 and 
Staphylococcus hominis S-Cys-Gly-3M3SH transporter PepTSh
147. The others are three related 
to multidrug efflux, EmrD ,YajR and MdfA from E.coli127,148,149; one deals with phosphate 
transfer from eukaryote Piriformospora indica150; three mediate nitrate exchange, including 
NarU151 and NarK152 from E.coli and NRT1.1 from eukaryote Arabidopsis thaliana153; one 
ferroprotein (FPN) Fe2+ transporter from Bdellovibrio bacteriovarus154. The details of 
structures solved MFS transporters are listed below (Table 1.1). 
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Table 1-1  All structure solved MFS transporters 
 
Name Description  Organism  PDB code Resolution limit 








E.coli 1PW4 3.3 
EmrD Mutidrug transporter E.coli 2GFP 3.5 
FucP L-Fucose:proton symporter  E.coli 3O7Q, 3O7P 3.1 




PepTst Peptide: proton symporter S.thermophilus 4APS, 4XNJ, 
4XNI ,5OXl, 5OXK, 
5OXM, 5OXN, 6EIA, 
5OXQ, 5OXP, 5OXO 
1.95 
GkPOT Peptide: proton symporter G.kaustophilus 4IKV, 4IKW, 4IKX, 
4IKY, 4IKZ 
2.0 
XylE D-Xylose:proton symporter E.coli 4GBY, 4GBZ, 4GC0, 
4JA3, 4JA4, 4QIQ 
2.6 
GlcP Glucose:proton symporter S.epidermidis 4LDS 3.2 
PiPT Phosphate:proton 
transporter 
P.indica (E) 4J05 2.9 
NarU Nitrate transporter E.coli 4IU9, 4IU8 3.01 
NarK Nitrate transporter E.coli 4JR9, 4JRE, 4U4V, 
4U4T, 4U4W 
2.35 
YajR Drug efflux:proton 
transporter 
E.coli 3WDO 3.15 
MelB Melibiose:sodium 
symporter 
S.typhimurium 4M64 3.35 
YbgH Peptide: proton symporter 
 
E.coli 4Q65 3.4 
NRT1.1 Nitrate transporter A.thaliana (E) 5A2N, 5A2O, 4OH3 3.25 
GLUT1 Glucose transporter Homo sapiens 4PYP, 5EQI, 5EQG, 
5EQH 
3.0 
YePEPT Peptide: proton symporter Y.enterocolitica 4W6V 3.02 
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Continued table 1-1  All solved structure of MFS transporters 
 
Name Description  Organism  PDB code Resolution limit 
MdfA Multidrug resistance 
transporter 
E.coli 4ZP0, 4ZOW, 4ZP2 2.0 
GLUT3 Glucose transporter Homo sapiens 4ZW9, 4ZWB, 4ZWC 1.5 







GLUT5 Fructose transporter Bos Taurus (E) 4YB9 3.2 
GLUT5 Fructose transporter Rattus 
norvegicus (E) 
4YBQ 3.27 
PepTXc Peptide: proton symporter X.campestris 6EI3 2.1 
PepTSh S-Cys-Gly-3M3SH 
transporter  
S.hominis 6EXS 2.5 
STP10 Glucose:protein 
symporter 
A.thaliana (E) 6H7D 2.4 
PfHT1 Hexose transporter P.falciparum 
(E) 
6RW3 3.65 
(E) indicates the protein originated from Eukaryote 
 
The overall structure of these transporters displays the classic MFS fold, presenting 12 TMs 
except transporters from the proton-dependent oligopeptide transporter (POT) family with 14 
TMs, such as PepTSo
141. These 12TMs are divided into two discretely folded domains (N-
domain and C-domain), related by a twofold pseudosymmetry axis perpendicular to the 
membrane plane (Fig. 1.12, Fig. 1.13 A). Previous bioinformatic evidence suggested that 12 
TMs are originated by a duplication of 3 TMs to 6 TMs and another duplication to 12 
TMs119,155, which is supported by structural features. TM4, TM5 and TM6 can be related to 
TM1, TM2 and TM3 by rotating around the axis parallel to the membrane bilayer; TM7, TM8, 
TM9 and TM10, TM11, TM12 can be related to each other in the same way121. Every first TM 
helices of the 3-TMs bundle, TM1, TM4, TM7 and TM10, are placed in the center of the 
transporter (Fig. 1.13), defining the interface of the substrate-binding pocket which is 
generally located in the half-way of the transporter120. TM3, TM6, TM9 and TM12 are 
positioned on the periphery of the TM1, TM4, TM7 and TM10 group (Fig. 1.13), and these 
are believed to be important for structural rigidity120. TM2, TM5, TM8 and TM11 sit on the 
sides of the transporter, mediating the interactions between the two sub-domains120(Fig. 1.13). 
The linking loops of the two domains are relatively long, some of which present a short α 





Fig. 1.12  Topology diagram of the MFS fold. TM 1,4,7,10 are colored in wheat; TM 2,5,8,11 are in 
light purple; TM 3,6,9,12 are shown in rose-red color. The loops are depicted in black. The short α helix 




Fig. 1.13  The overall architecture of a classical MFS transporter LacY. A: Inward-facing apo LacY 
(PDB code: 2CFQ). B: Top view of LacY. TM 1,4,7,10 are colored in wheat; TM 2,5,8,11 are in light 
purple; TM 3,6,9,12 are shown in rose-red color. The loops are depicted in gray.  
 
1.7.3 Substrate binding 
 
All MFS transporters contain a single substrate-binding pocket formed by residues from the 
N-domain and the C-domain120. The first ligand-bound MFS transporter structure XylE was 
obtained in 2012, shedding the light on transporter-substrate interaction from the structural 
standpoint134. Nowadays, there are six more solved substrate-bound structures from four 
families, including PepTSo with tri-peptides
157, PepTSt with di-peptides
158, nitrite or nitrate 
bound NarK152,159, nitrite bound NRT1.1153, multidrug resistance transporter MdfA with 
chloramphenicol160 and BbFPN with Fe2+ 154. Two general features of the ligand-binding 
pocket have been proposed: 1) only a few residues are involved in the interaction with the 
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substrate. 2) The two domains contribute asymmetrically to the interaction with the 
substrate120. Meanwhile, the binding pocket can be highly adaptable towards the nature of a 
specific substrate. A single Lys314 located in the binding pocket of YePEPT is crucial for the 
preference of negatively charged di-peptides, while its substitution to negatively charged Glu 
contributes to binding positively charged di-peptides instead145. Other residues located outside 
the binding pocket can also contribute to substrate recognition, which is often related to a 
specific physiological function. For instance, pfHT1 is a hexose transporter of malaria 
parasites that transports many hexoses besides glucose, while GLUT3 is a highly specific 
glucose transporter of humans137,140. pfHT1 was proposed to achieve its sugar promiscuity by 
coordinating with residues located in TM1-TM7b140. This sugar promiscuity was hypothesized 
to reduce the dependence on glucose after the parasite infects human red blood cells140.  
 
1.7.4 Proton Coupling 
 
Some MFS transporters are coupled with a second driving solute or several solutes to transfer 
their natural substrates. The coupled solutes can be Na+, H+, phosphate, etc.94 The ones coupled 
with protons can make use of the electrochemical energy called proton motive force generated 
by a gradient of H+ across the membrane (ΔμH+)156. The proton motive force is often utilized 
by bacteria to transfer substances against their concentration156. The movement of the substrate 
and the coupled proton can be in the same or the opposite direction, known as proton-coupled 
symporters and proton-coupled antiporters respectively156. Symporters are generally for 
substance (such as sugars, short peptides) up-taken and antiporters for effluxion (such as 
drugs)146,160–162.  
 
Some similarities of the proton coupling were proposed among different families including 
both proton-coupled symporters and antiporters146. A striking one is that the coupling sites are 
conserved within a family, generally happening in Glu, His and Asp located close to or inside 
the binding pocket127,130,132,135,146,149,161,163. These residues can undergo pKa changes during 
the conformational changes of the transporter and present the protonation and deprotonation 
process120. One of the fundamental questions regarding the proton coupling mechanism is how 
the proton coupling coordinates to the substrate binding and the conformational change. 
Researchers have intensively investigated these questions in the proton/lactose symporter 
LacY. The proton was hypothesized to transfer from Glu269 to His322, both of which 
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participate in the substrate binding164,165, and further, to Glu325164. Glu325 was identified to 
involve exclusively in protonation/deprotonation with a pKa 10.5, and its protonation was 
required for the binding of the substrate166. Arg306 was proposed to be essential to the 
deprotonation of Glu325167. The proton motive force was demonstrated to change the rate-
limiting step of the transport from deprotonation to opening the apo LacY 167.  
 
1.7.5 Alternating access 
 
MFS transporters achieve their substrate translocation through the membrane by the 
“alternating access” mechanism, namely the binding site is made accessible from one side of 
the membrane to another or in a reverse order168. MFS transporters generally adopt one of the 
alternating access models called the “Rocker switch” mechanism where the chronological 
opening is achieved by the conformational change between two sub-domains that transfers 
from the V-shape like outward-facing state to an inverted V-shape like inward-facing state168. 
Between the outward-facing and the inward-facing state is the intermediate occlude state168. 
Due to the structural asymmetry, namely, the asymmetrical contribution of two domains to the 
interaction with the substrate, transporter states can be further divided into the outward-
occluded or the inward-occluded conformation120,121. Accompanied by the conformational 




Fig. 1.14  The conformational change and the substrate translocation of MFS transporters. Adapted 
from120 
 
Multiple conformational states of some MFS transporters have been elucidated, providing 
insights into understanding the conformational change and the “Rocker switch” model. LacY 
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serves as the most intensively studied prototype of MFS transporters, being elucidated the 
outward-facing, the inward-facing and the occlude state169–172. The other two sugar 
transporters, XylE173,174and GLUT5138 were known the outward-facing structure and the 
inward-facing structure. Besides sugar transporters, transporters that mediate short 
peptides141,142, exchange nitrite/nitrate151,152 and transfer Fe2+154 have been characterized in 
more than one conformation. With the limited structural information, we have already 
proposed that the conformational change originates from both the rigid body movement, 
namely the overall domain rotation, and the local position rearrangement of the residues from 
TMs, especially from the TM1,4,7,10 which display more discontinuities compared to other 
TMs to satisfy a larger movement120,168. The rotation of the rigid body and rearrangement of 
local residues generally require the breakage and the re-formation of interactions (such as salt 
bridges and/or polar interactions) between gating residues which can seal the cytoplasmic side 
or the extracellular side of transporters during the transport cycle98,131,168,174. The binding and 
the release of the substrate were announced to encourage this breakage and re-formation, thus 
promoting the conformational change98,132,164. Coupling with driven solutes was also assumed 
to facilitate the substrate binding and conformational change135,161,175,176. Nevertheless, how 
are substrate binding and/or ion coupling involved in conformational change is still not well 
understood.  
 
1.8 Aims of this work  
 
S.aureus infection represents a threatening global health burden facilitated by its high 
adaptability to various harsh environments, notably, to the clinical usage of diverse antibiotics. 
LTA serves as a crucial component of the cell wall and plays a pivotal role in helping with 
S.aureus’ adaptation and antibiotic resistance. LtaA is an MFS flippase involved in the flipping 
of the glycolipid anchor Glc2-DAG which is a key brick of LTA assembly. No structure 
involved in glycolipid transporters belonging to MFS transporters is available. The molecular 
basis of LtaA function and mechanism remains largely unknown. Thus, solving the structure 
of LtaA will greatly promote the understanding of its substrate recognition and the flipping 
mechanism, establishing a framework for understanding MFS glycolipid transporters.  
 
Therefore, the primary goal of my project was to perform a structural study on LtaA, followed 
by its functional characterization in vitro and in vivo, to elucidate the translocation mechanism 
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of Glc2-DAG.    
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4   Discussion  
4.1 Stabilization and Crystallization of a Membrane Protein Involved in 
Lipid Transport 
 
X-ray crystallography is a robust technique to obtain the atomic structure of proteins and has 
been applied to solve 89% of the structures deposited in the PDB database 
(https://www.rcsb.org/stats/summary). However, only around 2% of them are membrane 
proteins and only 27 are MFS transporters (https://blanco.biomol.uci.edu/mpstruc/). By 
applying several tips, we successfully obtained high-quality LtaA crystals which were suitable 
for structure determination via vapor diffusion.  
 
Poly-His tag is a common affinity tag, applied in nearly 60% of solved protein structures177. 
Generally, the cleavage of the His-tag is a trivial factor to the final structure determination, 
because this small tag does not influence the native structure in general178. However, in the 
case of LtaA, N-terminal His10-tag cleavage led to a dramatic improvement of protein stability 
and mono-dispersity during the purification process, thus promoting the formation of high-
quality crystals. Indeed, the length of His-tag was proposed to influence the oligomeric state 
and the chromatographic behavior of some membrane proteins179. The improvement of LtaA 
mono-dispersity might be due to the decrease of unspecific interactions between LtaA 
monomers through the His-tag.  
 
One of the reasons for low-resolution X-ray diffraction is radiation damage. Cryogenic data 
collection has been commonly applied to reduce the radical damage to protein crystals caused 
by X-ray180. However, flash-cooling of protein crystals is believed to cause heterogeneous 
thermal contractions of crystal contents, thus increasing the orientational misalignment of 
molecular arrays and contributing to the dispersion of the Bragg diffraction peaks and low 
quality of diffraction data, specifically for crystals with large pores containing bulk-solution 
component181–183. “In situ annealing” that includes warming the flash-cooled crystal and flash 
cooling it again on the goniometer184, was demonstrated to be an effective way to reduce the 
crystal mosaicity caused by the flash-cooling process via allowing the reorder of mosaic blocks 
inside the crystalline, improving the data quality, such as obtaining better shaped, well ordered 
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and high-resolution spots and getting rid of ice rings185,186. According to the thermal 
contraction theory, the LtaA crystal, packaged in an orthorhombic space group with 71.94% 
solvent content, most likely would undergo the mismatch of the molecular arrays during flash-
cooling, resulting in diffractions only to a low-resolution range. Indeed, although LtaA crystals 
were formed by high-quality protein in a well-defined shape, the highest resolution of 
diffraction went to a low range (>7 Å). By applying the annealing, disordered molecular arrays 
might be realigned and diffract to a high-resolution range. Indeed, LtaA crystals diffracted to 
3-4 Å with better-defined patterns, dramatically promoting the final structure determination. 
Notably, the volume of the unit cell shrank 18% after annealing on average, indicating the 
protein molecules were packed tighter. Flash-cooling, as well as annealing, may change the 
unit cell size, varying from 1%-7%, partially contributed by the thermal expansion/contraction 
of the solvent content182,186,187. This significant contraction of the unit cell of LtaA might result 
from its high solvent content (71.94%), while the solvent content of former reported cases 
normally ranged from 20%-60%182–184,186. However, the effect of “in situ annealing” is also 
case-dependent186. Therefore, we recommend checking crystals case by case. Notably, the 
dramatic change of unit cell will introduce difficulties in applying the isomorphous 
replacement, due to different shrinking levels of native crystals and derivative crystals.       
 
4.2 Structure of a proton-dependent lipid transporter involved in 
lipoteichoic acids  
 
In this part of the project, we elucidated the structure of LtaA. The canonical MFS fold was 
observed, in agreement with other known MFS structures120. LtaA showed a large amphiphilic 
cavity formed by a hydrophilic half pocket (with an overall negative electrostatic surface 
potential) of N-domain and a hydrophobic half pocket of C-domain. MFS transporters were 
believed to evolve through multiple rounds of the duplication event, from the 6-TMs bundle 
to a further 12-TMs transporter119. The amphipathic property suggested the heterogeneous 
duplication through TMs bundles with different properties (such as a combination of a 
hydrophobic bundle and a hydrophilic bundle) to fit the requirement of amphiphilic substances 
translocation. This feature may help in identifying MFS transporters dealing with amphiphilic 
substances in silico. Although no typical amphipathic cavity of an MFS transporter that flips 
glycolipids has been elucidated, the amphipathic feature of the binding pocket was reported in 
Ph.D. Dissertation of University of Basel 
 60 
MFS transporters, such as GluP135 that transfers glucose and FucP188 mediating fucose 
transport. Notwithstanding that the binding cavity is amphiphilic, both glucose and fucose 
were proposed to interact with the hydrophilic part of the cavity135,188. This feature highlighted 
the importance of the hydrophilic half pocket in sugar moiety recognition, which was 
reminiscent of the potential interaction between the glucosyl group of Glc2-DAG and the 
hydrophilic half pocket of LtaA. We performed the docking analysis in silico and found that 
the disaccharide group could be indeed accommodated by the hydrophilic half pocket. Thus, 
we further conducted flipping assays with the addition of different disaccharides as 
competitors of Glc2-DAG. The inhibition effect of the gentiobiose but not the lactose, fructose 
or trehalose clearly pointed out that LtaA recognized the di-glucosyl moiety of Glc2-DAG 
precisely and specifically. The inhibition effect also suggested that the di-glucosyl moiety 
might serve as a template for the design of potential inhibitors of LtaA, providing a concept 
of drug design.  
 
We selected residues including E32, R35, D68, W127 and W150 showed potential interactions 
with the di-glycosyl region, mutated to alanine and subjected to flipping assays. However, 
these mutants did not show a big change in the flipping ability. It might be that the single-point 
mutation was not enough to interrupt the recognition and loading since the substrate is big and 
may form multiple interactions with LtaA. Several double-point mutations including 
E32A/D68A, R35A/D68A, W150A/D68A were further investigated, and we found that they 
displayed a significant reduction of their flipping activity, which was consistent with our 
structural analysis. Our data supported a model in which LtaA loads the Glc2-DAG to its 
central cavity from lipids pool through the recognition of the di-glucosyl moiety by 
hydrophilic residues including E32, R35, D68 and W150 in the N-domain. This brought 
insights into the recognition mechanism of other MFS transporters mediating glycolipid 
flipping.  
 
Notably, three charged residues, E32, R35 and D68 were positioned in proximity of the 
binding pocket. They might undergo protonation/deprotonation during conformational shifts 
of LtaA, fitting the typical feature of MFS proton-dependent transporters142,146,148,149,156,160,163. 
We verified this hypothesis by performing flipping assays under different pH gradients. We 
observed that the flipping activity of LtaA responded to different pH gradients. When an 
inward proton gradient (lower pH outside the liposome) appeared, more Glc2-DAG molecules 
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were transported to the outside of the liposome compared to the one without a proton gradient. 
Correspondingly, an outward proton gradient (higher pH outside the liposome) led to less Glc2-
DAG transported to the outside of the liposome. Based on this, we demonstrated that LtaA 
behaves as a proton-dependent antiporter. To identify which residues carry on the proton 
transfer, we calculated the theoretical pKa value of E32, R35 and D68 under the current 
outward-facing conformation, with 7.8, 14, 3.4 respectively. We postulated that E32 was most 
likely the protonation/deprotonation site, which was verified in the flipping assay where the 
E32A mutant lost the response to pH gradients. Herein, a proton-coupling mechanism of LtaA 
was proposed that after the release of the Glc2-DAG, E32 would be protonated, facilitating the 
transition from the outward-facing stage to an inward-facing state, where it would undergo 
deprotonation.  
 
However, whether other residues participate in the proton transfer is not known. The trait of 
the proton-coupling of LtaA also highly resembles proton-dependent MFS sugar 
transporters135,161,188,189, even though they are all symporters. An interesting fact is that MFS 
glucose transporters of bacteria are often proton-coupled, while their homologs in humans are 
commonly uniporters135, even though both of them contain a conserved Glu residue serving 
as the primary protonation/deprotonation site135. The loss of proton-coupling in many human 
glucose uniporters was attributed to the substitution of a critical Asp residue to an Asn near 
Glu, which disrupted the proton-coupling environment135. In our docking model, an Asp 
residue (D68) was close to the protonation/deprotonation site E32, indicating D68 might also 
participate in the proton-coupling mechanism. Indeed, we observed impaired growth of the 
D68A mutant under the acidic condition in S.aureus, implicating D68 involves in the proton-
coupling network.    
 
The aliphatic tails were proposed to fit into the hydrophobic pocket formed by the C-terminal 
domain. This showed similarities to the interaction between MurJ and the lipid moiety of lipid 
II111,190 (Fig. 4.1). In MurJ, a hydrophobic groove formed by TM 13 and 14 contributed to 
accommodating the lipid tails191. The specific hydrophobic region might be a general feature 
of secondary transporters to accommodate the hydrophobic moieties of amphiphilic molecules, 
which might be exerted to identify new secondary transporters dealing with amphiphilic 
substrates in silico.  
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Fig. 4.1  Electrostatic potential surface representatives of MurJ (A) and LtaA (B). A. Hydrophobic 
extended groove formed by TM13 and TM14 of MurJ highlighted by black circles. PDB: 6CC4. 
Adapted from191 B. The hydrophobic half pocket highlighted by a black circle of LtaA. Transporters are 
colored in rainbow. 
 
Overall, our structural and biochemical characterization on LtaA established a framework for 
understanding the mechanism of proton-dependent MFS antiporters and MFS glycolipid 
transporters.  
 
ABC-transporters are frequently involved in glycolipid transport100. The structures of known 
ABC-transporter flippases show that sometimes lipid moieties of substrates are bound in the 
internal cavity of the transporter, but in other cases, they were proposed to stay in the 
membrane rather104,106,107. A similar question remains in the case of LtaA. It was suggested 
that one of the lipid tails might be left in the membrane from the docking analysis. Capturing 
other states (such as the inward-facing and the occluded conformation), as well as a substrate-
bound structure, will provide direct evidence to clarify whether a “credit card” or “trap and 
flip” model is applied by LtaA.  
 
It’s mentioned above that glucose transporters of humans are often uniporters while the ones 
from bacteria tend to couple with protons. Human glucose transporters were hypothesized to  
lose their proton coupling ability because they are always exposed to sufficient glucose, while 
bacteria glucose transporters are coupled with protons to enhance their utility of the low 
concentration of glucose in the environment135. This difference highlights the biological 
relevance of the proton-coupling mechanism. In S.aureus, the natural substrate Glc2-DAG is 
synthesized inside the cytoplasm by YpfP constantly, followed by the export to extracellular45. 
This can set up an outward Glc2-DAG gradient which can be applied as the energy source for 
its movement45. Indeed, we observed that the E32A mutant maintained a base level of the 
flipping activity which was comparable to the WT LtaA without a proton gradient. Therefore, 
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we were wondering about the physiological relevance of the proton-coupling of LtaA. 
 
S.aureus can colonize acidic niches including the skin, nasal mucus and host macrophages192–
194. An acidic environment is harmful to S.aureus cells, leading to the acidification of the 
cytoplasm, therefore affecting the activity of enzymes, the electron transport chain as well as 
the DNA structure due to the protonation of nitrogenous bases195. Therefore, S.aurues possess 
specific genes to confer acidic resistance. Suggested by the proton coupling of LtaA and the 
colonization of S.aureus under acidic environments, we speculated that the proton coupling 
mechanism might of LtaA contribute to the acidic resistance of S.aureus. To figure it out, 
intrinsic ltaA was knocked out in S.aureus NCTC 8325 and complementary plasmids carrying 
WT or mutant ltaA were transformed to S.aureus, followed by inspections on the growth state 
and the cell morphology under acidic environments, either by adjusting the pH value of 
medium or providing 5% CO2 (acidify the medium to around pH 6). LtaA could work as a 
“pH-sensing” transporter in the presence of low external pH, flipping Glc2-DAG at a higher 
rate by utilizing the energy generated by the pH gradient. More Glc2-DAG flipped to the outer 
leaflet of the plasma membrane leads to an enhanced level of LTA assembly. Extra LTA 
molecules form a stronger mesh that can enhance the mechanical rigidity of the cell wall. 
Meanwhile, the newly formed LTA molecules increase the overall negative charge and protect 
S.aureus from acidic harm probably owing to a “buffering effect”. Our results, for the first 
time, provided strong evidence that the Glc2-DAG flippase LtaA contributes to the acidic 
resistance of S.aureus.  
 
The acidic tolerance mechanism of S.aureus has been studied for many years. Two major 
classes of genes are involved in developing acidic tolerance. One type is responsible for 
sensing the acidic stimulus, including two-component system GraXRS194, cytoplasmic 
regulators such as sigma factor sigB and sarA from the SarA family196–198, GdpP from the 
additional signal transduction protein system and its downstream target second messenger c-
di-AMP197,199. The other cluster serves as the response apparatus. At least four categories of 
genes have been identified to respond to acidic tolerance in at least two ways. The first way is 
to consume excess protons via metabolic reactions in the cytoplasm, and related genes are 
upregulated, including genes involved in urease function200,201, acetolactate 
synthase/decarboxylase function202,203 and the arginine deiminase pathway195,204. The second 
way is to promote the excretion of protons. ATP can be generated in the arginine deiminase 
Ph.D. Dissertation of University of Basel 
 64 
pathway, then taken by specific ATPases to expel protons from the cell195,204. Besides, many 
other factors also have been reported to involve in the acidic resistance, such as the reactive 
oxygen species (ROS) clusters195 and superoxide dismutase sodA205.  
 
Different from all types of genes proposed, LtaA is the first identified glycolipid flippase 
involved in acidic tolerance among bacteria to our knowledge, hinting at the complexity and 
diversity of the acidic resistance regulatory network of bacteria. Another striking feature is 
that LtaA combines the stimuli-sensing and the effectuating modules, which are generally 
implemented by different proteins. The proton coupling of the transporter acts as the “sensing 
module” and the response module is achieved by accelerating the flipping activity which leads 
to the enhanced LTA assembly level. This combination of “sensing” and “effectuating” allows 
a fast and potent response to combat the acidic stress. Our research brought new insights into 
understanding the mechanism of the acidic resistance.  
 
During the growth state investigation of the LtaA knockout strain, several simultaneous 
suppressors that could rescue the growth defects were identified. A gdpP mutant partly rescued 
the growth defect of S.aurues under acidic stress, in agreement with a previous report199. This 
gdpP mutant allowed an enhanced level of cellular c-di-AMP and contributed to cell wall 
integrity206–208. Our result indicated that LtaA cooperates with other acidic-resistant proteins 
but the mechanism is not known. If there are interactions between LtaA and other factors 
involved in the acidic resistance also remains an attractive question.   
 
Both acidic resistance and antibiotic resistance render S.aureus a versatile human pathogen. 
The cross-talking between mechanisms of acidic tolerance and antibiotic resistance has been 
observed. The exposure to the acidic environment (pH<5.5) enhanced the susceptibility of 
MRSA strains to antibiotics such as benzylpenicillin, Methicillin, meropenem and 
cloxacillin27,209,210. An enhanced level of Glc2-DAG in the membrane was reported in clinical 
isolates with antibiotic resistance compared to antibiotics susceptible strains211.  
 
In a previous study, the growth arrest was not observed in the LtaA knockout strain under 
standard laboratory conditions44. Our result highlighted a pivotal condition, the acidic 
environmental pH, making LtaA a decisive factor for S.aureus viability. Our study suggested 
that for bacteria colonizing an acidic environment, such as S.aureus, a standard culturing 
4  Discussion 
 65 
protocol might conceal the specific feature of the target and underestimate its physiological 
significance. Our findings would encourage additional studies on proton-coupled antiporters 
of other human pathogens that can survive under acidic niches. This eventually will help in 
identifying new potential anti-bacterial targets.  
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5   Conclusion and outlook 
 
In this project, we determined the atomic structure of LtaA at 3.3Å (PDB code: 6S7V), 
investigated the molecular basis of the recognition of the substrate Glc2-DAG and proposed a 
proton-coupled flipping mechanism. Furthermore, we revealed an unprecedented function of 
LtaA in S.aureus acidic resistance and figured out its regulatory mechanism. Our results set a 
framework for understanding the mechanism of MFS glycolipid transporters, contributed to 
the comprehension of S.aureus pathogenesis and provided a novel target for anti-S.aureus 
therapeutics.  
 
One of the crucial questions of flippase research is to illustrate the mechanism of substrate 
recognition and binding. We have already identified crucial residues involved in Glc2-DAG-
LtaA interaction by performing in vitro biochemical assays. However, how does LtaA flip the 
lipid tails, such as by a “credit card” model or a “trap and flip” model, remains enigmatic. 
Solving substrate-bound structures would provide direct evidence to address this question. A 
co-crystallization or a soaking strategy can be applied to get the substrate-bound complex. 
Besides obtaining this structure, flipping assays with different lengths of Glc2-DAG as 
competitors will also contribute to illustrate whether the lipid tails are enclosed by the binding 
pocket from a biochemical perspective. Another question is to figure out the molecular basis 
of conformational changes. Obtaining an inward-facing state of LtaA would help with the 
analysis of local rearrangements of residues involved in conformational changes. LtaA with 
gating residues cross-linked on the extracellular side would help to lock the inward-facing 
during the crystallization. As mentioned above, D68 might participate in proton-coupling. To 
verify it, a neutral mutation to Asn can be constructed and subjected to flipping assays under 
different pH gradients.  
 
The substrate Glc2-DAG is synthesized by a membrane-associated protein YpfP, whose coding 
sequence overlaps to the start of LtaA44. Expression of YpfP in E.coli produced Glc2-DAG and 
triglucosyl-diacylglycerol (Glc3-DAG)
212, while co-expression of LtaA and YpfP only 
produced Glc2-DAG
44,212, indicating a function of LtaA in regulating the number of sugars 
added by YpfP. Thus, we assumed that there might be physical contacts between LtaA and 
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YpfP. A pull-down assay can be carried out first to see if there are interactions. To further 
clarify it, LtaA and YpfP can be co-purified, followed by the crystallography or cryo-EM study.  
 
    
      
 





ATP adenosine triphosphate  
ABC transporters ATP-binding cassette transporters 
CAMPs cationic antimicrobial peptides  
c-di-AMP cyclic-di-adenosine monophosphate  
DAG diacylglycerol  
Glc2-DAG diglucosyl-diacylglycerol  
E. coli Escherichia coli 
et al. et alia 
etc. et cetera 
LPS lipopolysaccharide  
LTA lipoteichoic acids 
LtaA lipoteichoic acid protein A 
MFS major facilitator superfamily  
MRSA methicillin-resistant S. aureus  
NBDs nucleotide-binding domains  
PDB protein data base 
PG peptidoglycan 
PBPs penicillin-binding proteins 
S.aureus Staphylococcus aureus  
TM transmembrane 
TMDs transmembrane domains 
TMs transmembrane helices 
TLR2 Toll-like receptors 2  
UDP-Glc uridine diphosphate glucose 
Und-PP undecaprenol pyrophosphate  
VRSA vancomycin-resistant S. aureus  
WTA wall teichoic acids 
WT wildtype 







Amino acid One-letter code  Three-letter code  
Alanine A Ala 
Aspartate D Asp 
Cysteine C Cys 
Glutamate E Glu 
Phenylalanine F Phe 
Glycine G Gly 
Histidine H His 
Isoleucine I Ile 
Lysine  K Lys 
Leucine  L Leu 
Methionine  M Met 
Asparagine  N Asn 
Proline  P Pro 
Glutamine  Q Gln 
Arginine  R Arg 
Serine  S Ser 
Threonine  T Thr 
Valine  V Val 
Tryptophan   W Trp 
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